發(fā)布時(shí)間：2018-03-12 22:05

  本文選題：升降散　切入點(diǎn)：栓塞后綜合征　出處：《河南中醫(yī)藥大學(xué)》2016年碩士論文　論文類型：學(xué)位論文

【摘要】：目的:初步探討升降散對(duì)原發(fā)性肝癌栓塞后綜合征的臨床療效的影響,為原發(fā)性肝癌栓塞后綜合征的中醫(yī)藥治療提供客觀的臨床依據(jù)。方法:選取符合入選標(biāo)準(zhǔn)原發(fā)性肝癌患者病例60例,按照隨機(jī)數(shù)字表法進(jìn)行隨機(jī)分組。隨機(jī)等分為治療組30例,對(duì)照組30例。對(duì)照組栓塞后給予西醫(yī)常規(guī)治療,包括靜脈補(bǔ)液、抗炎等治療。治療組在對(duì)照組治療基礎(chǔ)上,于術(shù)后第1天至術(shù)后第7天服用升降散,連服7天。兩組均治療7天,觀察兩組患者發(fā)熱、惡心嘔吐、肝區(qū)疼痛、便秘癥狀的發(fā)病程度及持續(xù)時(shí)間。結(jié)果:1.對(duì)比治療組與對(duì)照組患者發(fā)熱、惡心嘔吐、肝區(qū)疼痛、便秘癥狀栓塞治療前無(wú)顯著性差異(P0.05);栓塞治療后第1天至第7天的對(duì)比治療組與對(duì)照組患者,發(fā)熱、惡心嘔吐、肝區(qū)疼痛、便秘癥狀的在術(shù)后第3天至術(shù)后第6天發(fā)生程度差異顯著(P0.05);2.栓塞治療后7天,對(duì)比治療組與對(duì)照組患者的發(fā)熱、惡心嘔吐、肝區(qū)疼痛、便秘癥狀的持續(xù)時(shí)間差異顯著(P0.05)。結(jié)論:1.升降散能有效減輕原發(fā)性肝癌栓塞后綜合征的發(fā)病程度;2.升降散能有效減少栓塞后綜合征的持續(xù)時(shí)間。
[Abstract]:Objective: to explore the effect of Shengsheng Powder on the clinical effect of primary liver cancer after embolization syndrome. Methods: 60 patients with primary hepatocellular carcinoma (PHC) were selected and randomly divided into treatment group (n = 30) according to random digital table method. The control group (30 cases) was treated with routine western medicine after embolization, including intravenous fluid resuscitation, anti-inflammatory therapy and so on. The treatment group was treated on the basis of the control group from the first day after operation to the seventh day after operation. For 7 days, both groups were treated for 7 days. The incidence and duration of fever, nausea and vomiting, liver pain, constipation symptoms and constipation symptoms in the two groups were observed. Results: 1.Fever, nausea, vomiting and pain in liver region were compared between the treatment group and the control group. There was no significant difference in constipation symptoms before and after embolization (P 0.05). The patients in the control group and the control group had fever, nausea and vomiting, and pain in the liver area from day 1 to day 7 after embolization. The degree of constipation symptoms was significantly different from the 3rd day to the 6th day after operation (P 0.05). 7 days after embolization, fever, nausea and vomiting, pain in the liver area were compared between the treatment group and the control group. The duration of constipation symptoms was significantly different from that of P0.050.Conclusion: 1. Shengghangsan can effectively reduce the severity of post-embolism syndrome of primary hepatocellular carcinoma (PHC). It can effectively reduce the duration of post-embolism syndrome.
【學(xué)位授予單位】：河南中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2016
【分類號(hào)】：R273

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 竇浩生;王艷紅;高詠梅;;肝癌介入治療后“栓塞后綜合征”的預(yù)防處理及臨床觀察[J];當(dāng)代醫(yī)學(xué);2010年29期

2 馬海慶;魏濤;池永娥;;肝癌TACE術(shù)后“栓塞后綜合征”的預(yù)防和治療[J];中外醫(yī)學(xué)研究;2011年16期

3 岑瑤;楊承蓮;陳莉;汪霞;;子宮肌瘤子宮動(dòng)脈栓塞后綜合征的護(hù)理[J];四川腫瘤防治;2007年03期

4 潘長(zhǎng)春;唐承富;王曉秋;胡偉堅(jiān);;垂體后葉素治療肝癌栓塞后綜合征的效果[J];實(shí)用醫(yī)學(xué)雜志;2007年13期

5 林鈞華，，倪惠芳，李國(guó)安，易成，黃挺;中西醫(yī)結(jié)合治療肝癌介入栓塞后綜合征[J];上海中醫(yī)藥雜志;1995年10期

6 張寶南;尤建良;;微調(diào)3號(hào)方防治肝介入術(shù)后綜合征療效觀察[J];遼寧中醫(yī)雜志;2007年07期

7 張濤;盧娜;杜小瀅;田銀娣;張慧;李靜靜;;健康教育在肝癌肝動(dòng)脈灌注化療栓塞57例中的應(yīng)用[J];交通醫(yī)學(xué);2013年01期

8 鐘毅,周紅,陳春泳;甘露消毒丹 加味治療原發(fā)性肝癌介入栓塞后綜合征50例[J];河南中醫(yī);2002年04期

9 胡秉芹;周里萍;宮秀美;;肝動(dòng)脈插管栓塞化療的護(hù)理[J];工企醫(yī)刊;2006年05期

10 白莉;;中西醫(yī)結(jié)合治療肝癌介入栓塞后綜合征34例[J];中醫(yī)研究;2009年02期

相關(guān)碩士學(xué)位論文 前2條

1 柳云飛;升降散治療原發(fā)性肝癌栓塞后綜合征的臨床療效觀察[D];河南中醫(yī)藥大學(xué);2016年

2 陳文真;肝泰合劑治療肝癌栓塞后綜合征的臨床研究[D];福建中醫(yī)學(xué)院;2006年

本文編號(hào)：1603485